Longevity Fund

longevity.vc

VCMatch tracks Longevity Fund as an investor focused on Biotech and Pharma companies, Pre-Seed and Seed rounds, and United States, Silicon Valley, and Boston markets. Upload your deck to compare your startup against the full private matching profile.

Check Size

Not specified

Stages

Pre-Seed, Seed, Series A

Focus Areas

Biotech, Pharma

Geography

United States, Silicon Valley, and Boston

Investment Thesis

The firm invests to accelerate development of longevity medicines by backing mission-oriented, founder-led companies—especially early-stage or first-time founders with unconventional backgrounds—who can think differently about regulatory, scientific and company-building paths to get longevity-related drugs into human trials. They emphasize clinical proof in humans as the pivotal milestone that will attract mainstream pharma, capital and talent, and they value long time horizons and founder control to build the companies that can deliver the first approved longevity therapies.

Is Longevity Fund right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

Longevity Fund is most relevant for founders raising Pre-Seed, Seed, and Series A rounds in Biotech and Pharma, especially across United States, Silicon Valley, and Boston.

Focus statement

Focused on longevity biotech: funding founder-driven companies developing therapeutics to increase healthy human lifespan (initially via age-related disease indications and getting drugs into the clinic), with emphasis on early, unconventional founders and novel regulatory/company-building strategies.

Value Add

Explicit, narrow focus on longevity medicines and getting drugs for longevity into the clinic (not general biotech).
Preference for first-time or early-career founders with unconventional backgrounds: "We’re betting that first-time (or early career founders) with unconventional backgrounds are much more likely to do well here than in other areas of biotech".
Belief that mission-oriented founders who "truly care about the field" are essential: "You have to *truly care about the field *to build a longevity company–this kind of person is not going to be a CEO for hire."
Operates an accelerator / founder-focused playbook (started an accelerator in 2018 and branded subsequent fund age1) to test and scale founder-driven longevity companies.
Thesis framed around a time-bound opportunity: "THIS IS THE DECADE IN WHICH WE GET DRUGS FOR LONGEVITY INTO THE CLINIC."